Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers
Status:
Terminated
Trial end date:
2018-11-22
Target enrollment:
Participant gender:
Summary
The DaRifi study aims:
1. Develop adjusted doses of darunavir/ritonavir for use in HIV-infected patients requiring
co-treatment of TB with a rifampicin-based regimen.
2. Compare the steady state pharmacokinetics of doubled doses of DRV/r with rifampicin (in
once daily and 12-hourly approaches) to standard daily doses without rifampicin.
3. Twenty-eight volunteers will be enrolled for a target of 24 participants completing the
study.
Phase:
Phase 1
Details
Lead Sponsor:
University of Cape Town
Collaborators:
Desmond Tutu HIV Centre Wits Reproductive Health and HIV Institute